tirzepatide stamford ct Peptide of the Week: Tirzepatide, a Game Changer for Type 2 Diabetes and Obesity Management GLP-1 Weight Loss Plan -
Description
Zepbound is approved for chronic weight management and for obstructive sleep apnea in adults with obesity
After one year, people receiving tirzepatide had an average of 27.4 fewer apnea events per hour, compared to an average reduction of 4.8 events per hour for those in the placebo group
Make sure at least 72 hours have passed
The true frequency is still being investigated by medical authorities
Uncertain or no You will likely regain most weight
Adapted from Wadden et al
